Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp

European Journal of Endocrinology

Volumn 134, Issue 2, 1996, Pages 197-200

  Hartling, Svend G ^a,b   Røder, Michael E ^a   Dinesen, Bo ^a   Binder, Christian ^a  

^a STENO DIABETES CENTER   (Denmark)

^b AMAGER HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; PROINSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030030164     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1340197     Document Type: Article

References (27)

1. Madsbad S, Hartling SG, Faber OK. C-Peptide and proinsulin. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors. The international textbook of diabetes mellitus. New York: Wiley, 1991:303-32
2. Mako ME, Starr JI, Rubenstein AH. Circulating proinsulin in patients with maturity onset diabetes. Am J Med 1977;63:865-9
3. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte Jr D. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698-702
4. Glaser B, Leibowich G, Nesher R, Hartling SG, Binder C, Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copenh) 1988;118:365-73
5. Deacon CF, Schleser-Mohr S, Ballmann M, Willms B, Conlon JM, Creutzfeldt W. Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copnh) 1988;119:549-54
6. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1988;31:355-60
7. Temple RC, Luzio SD, Schneider AE, Carrington CA, Owens DR, Sobey WJ, et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989;1:293-5
8. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, et al. Disproportionately elevated proinsulin in Pima indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1990;70:1247-53
9. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte D Jr. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab 1992;74:192-7
10. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN. et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-8
11. Gorden P, Sherman BM, Simopoulos AP. Glucose tolerance with hypokalemia: an increased proportion of circulating proinsulin-like component. J Clin Endocrinol Metab 1972;34:235-40
12. Rosenbloom AL, Starr JI, Juhn D, Rubenstein AH. Serum proinsulin in children and adolescents with chemical diabetes. Diabetes 1975;24:753-7
13. Røder ME, Eriksson J, Hartling SG, Groop L, Binder C. Proportional proinsulin responses in first-degree relatives of patients with type 2 diabetes mellitus. Acta Diabetol 1993;30:132-7
14. Hartling SG, Garne S, Binder C, Heilmann C, Petersen W, Petersen KE, et al. Proinsulin, insulin and C-peptide in cystic fibrosis after an oral glucose tolerance test. Diabetes Res 1988;7:165-9
15. Heding LG. Radioimmunological determmation of human C-peptide in serum. Diabetologia 1975;11:541-8
16. Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, et al. Characterization of seven C-peptide antisera. Diabetes 1978;27 Suppl 1:170-7
17. Hartling SG, Dinesen B, Kappelgård A-M, Faber OK, Binder C. ELISA for human proinsulin. Clin Chim Acta 1986;156:289-97
18. Leahy JL, Weir GC. Evolution of abnormal insulin secretion responses during 48-h in vivo hyperglycemia. Diabetes 1983;37:217-22
19. Nauck MA, Siegel EG, Creutzfeldt W. Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. Pancreas 1991;6:645-52
20. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Bergenstal R, et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 1984;33:762-70
21. Bergenstal RM, Cohen RM, Lever E, Polonsky K, Jaspan J, Blix PM, et al. The metabolic effects of biosynthetic human proinsulin in individuals with type 1 diabetes. J Clin Endocrinol Metab 1984;58:973-9
22. Nauck MA, Stöckmann F, Thiery J, Ebert R, Creutzfeldt W. Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments. Horm Metab Res Suppl 1988;18:60-8
23. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 1986;77:98-105
24. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, et al. Kinetics of human connecting peptide in normal and diabetic subjects J Clin Invest 1978;62:197-203
25. Melani F, Rubenstein AH, Steiner DF. Human serum proinsulin. J Clin Invest 1970;49:497-507
26. Koivisto VA, Yki-Järvinen H, Hartling SG, Pelkonen R. The effect of exogenous hyperinsulinemia on proinsulin secretion in normal man. obese subjects and patients with insulinoma. J Clin Endocrinol Metab 1986;63:1117-20
27. Ward WK, Wallum BJ, Beard JC, Taborsky Jr GJ, Porte Jr D. Reduction of glycemic potentiation: sensitive indicator of B-cell loss in partially pancreatectomized dogs. Diabetes 1988;37:723-9